tradingkey.logo

Cidara Therapeutics Announces Positive Topline Results From Its Phase 2B Navigate Trial

ReutersJun 23, 2025 11:02 AM

- Cidara Therapeutics Inc CDTX.O:

  • CIDARA THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM ITS PHASE 2B NAVIGATE TRIAL EVALUATING CD388, A NON-VACCINE PREVENTATIVE OF SEASONAL INFLUENZA

  • CIDARA THERAPEUTICS INC - STUDY MEETS PRIMARY AND SECONDARY EFFICACY ENDPOINTS

  • CIDARA THERAPEUTICS INC - CD388 DOSES SHOW 76%, 61%, AND 58% PROTECTION FROM INFLUENZA

  • CIDARA THERAPEUTICS INC - CD388 WELL-TOLERATED WITH NO SAFETY SIGNALS OBSERVED

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI